Exploring structural features of EGFR–HER2 dual inhibitors as anti-cancer agents using G-QSAR approach

References

• Raghavendra NM, Pingili D, Kadasi S, et al. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem. 2018;143:1277–1300.
   PubMed Web of Science ®Google Scholar
• Fu R, Sun Y, Sheng W, et al. Designing multi-targeted agents: an emerging anticancer drug discovery paradigm. Eur J Med Chem. 2017;136:195–211.
   PubMed Web of Science ®Google Scholar
• Medina P, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426–1447.
   PubMed Web of Science ®Google Scholar
• Awada G, Gombos A, Aftimos P, et al. Emerging drugs targeting human epidermal growth factor receptor 2 (Her2) in the treatment of breast cancer. Expert Opin Emerg Drugs. 2016;21(1):91–101.
   PubMed Web of Science ®Google Scholar
• Agarwal SM, Pal D, Gupta M, et al. Insight into discovery of next generation reversible TMLR inhibitors targeting EGFR activating and drug resistant T790M mutants. Curr Cancer Drug Targets. 2017;17(7):617–636.
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009;6(6):352–366.
   PubMed Web of Science ®Google Scholar
• Yadav IS, Singh H, Khan MI, et al. EGFRIndb: epidermal growth factor receptor inhibitor database. Anticancer Agents Med Chem. 2014;14(7):928–935.
   PubMed Web of Science ®Google Scholar
• Ghorab MM, Alsaid MS, Soliman AM, et al. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors. J Enzyme Inhib Med Chem. 2018;33(1):67–73.
   PubMed Web of Science ®Google Scholar
• Yin S, Tang C, Wang B, et al. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold. Eur J Med Chem. 2016;120:26–36.
   PubMed Web of Science ®Google Scholar
• Gavai AV, Fink BE, Fairfax DJ, et al. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yl] carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J Med Chem. 2009;52:6527–6530.
   PubMed Web of Science ®Google Scholar
• Elkamhawy A, Farag AK, Viswanath ANI, et al. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted4-anilinoquinazoline hybrids: design, synthesis, kinase assay, cell-based assay, and molecular docking. Bioorg Med Chem Lett. 2015;25(22):5147–5154.
   PubMed Web of Science ®Google Scholar
• Prada-Gracia D, Huerta-Yépez S, Moreno-Vargas LM. Application of computational methods for anticancer drug discovery, design, and optimization. Bol Med Hosp Infant Mex. 2016;73(6):411–423.
   PubMed Web of Science ®Google Scholar
• Sliwoski G, Kothiwale S, Meiler J, et al. Computational methods in drug discovery. Pharmacol Rev. 2014;66(1):334–395.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Nandekar PP, Sangamwar A, et al. Structure guided design and binding analysis of EGFR inhibiting analogues of erlotiniband AEE788 using ensemble docking, molecular dynamics and MM-GBSA. RSC Adv. 2016;6(70):65725–65735.
   Web of Science ®Google Scholar
• De Oliveira MT, Katekawa E. On the virtues of automated quantitative structure–activity relationship: the new kid on the block. Future Med Chem. 2018;10(3):335–342.
   PubMed Web of Science ®Google Scholar
• Barzegar A, Zamani-Gharehchamani E, Kadkhodaie-Ilkhchi A. ANN QSAR workflow for predicting the inhibition of HIV-1 reverse transcriptase by pyridinone non-nucleoside derivatives. Future Med Chem. 2017;9(11):1175–1191.
   PubMed Web of Science ®Google Scholar
• Cherkasov A, Muratov EN, Fourches D, et al. QSAR modeling: where have you been? Where are you going to? J Med Chem. 2014;57(12):4977–5010.
   PubMed Web of Science ®Google Scholar
• Wang T, Wu M, Lin J, et al. Quantitative structure–activity relationship: promising advances in drug discovery platforms. Expert Opin Drug Discov. 2015;10(12):1283–1300.
   PubMed Web of Science ®Google Scholar
• Ajmani S, Kulkarni SA. Application of GQSAR for scaffold hopping and lead optimization in multitarget inhibitors . Mol Inform. 2012;31(6–7):473–490.
   PubMed Web of Science ®Google Scholar
• Ajmani S, Agrawal A, Kulkarni SA. A comprehensive structure–activity analysis of protein kinase B-alpha (Akt1) inhibitors. J Mol Graph Model. 2010;28(7):683–694.
   PubMed Web of Science ®Google Scholar
• Goswami D, Goyal S, Jamal S, et al. G-QSAR modeling and combinatorial library generation of 4-phenylquinazoline-2-carboxamide derivatives as antiproliferative agents in human glioblastoma tumors. Comput Biol Chem. 2017;69:147–152.
   PubMed Web of Science ®Google Scholar
• Fatima S, Gupta P, Agarwal SM. Insight into structural requirements of antiamoebic flavonoids: 3D-QSAR and G-QSAR studies. Chem Biol Drug Des. 2018;92(4):1743–1749.
   PubMed Web of Science ®Google Scholar
• Fatima S, Pal D, Agarwal SM. QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors. Chem Biol Drug Des. 2019;94(1):1306–1315.
   PubMed Web of Science ®Google Scholar
• Kawakita Y, Banno H, Ohashi T, et al. Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders. J Med Chem. 2012;55(8):3975–3991.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Seto M, Banno H, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem. 2011;54(23):8030–8050.
   PubMed Web of Science ®Google Scholar
• Kawakita Y, Miwa K, Seto M, et al. Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. Bioorg Med Chem. 2012;20(20):6171–6180.
   PubMed Web of Science ®Google Scholar
• ChemAxon. [cited 2019 Aug 20]. Available from: http://www.chemaxon.com
   Google Scholar
• VLifeMDS: Molecular Design Suite, Version 4.6, VLife Sciences Technologies Pvt. Ltd., Pune, India. [cited 2019 Aug 20]. Available from: www.vlifesciences.com
   Google Scholar
• Ajmani S, Jadhav K, Kulkarni SA. Group-based QSAR (G-QSAR): mitigating interpretation challenges in QSAR. QSAR Comb Sci. 2009;28(1):36–51.
   Google Scholar
• Khan PM, Roy K. Current approaches for choosing feature selection and learning algorithms in quantitative structure–activity relationships (QSAR). Expert Opin Drug Discov. 2018;13(12):1075–1089.
   PubMed Web of Science ®Google Scholar
• Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model. 2002;20(4):269–276.
   PubMed Web of Science ®Google Scholar
• Golbraikh A, Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. Mol Divers. 2000;5(4):231–243.
   Web of Science ®Google Scholar
• Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inform. 2010;29(6–7):476–488.
   PubMed Web of Science ®Google Scholar
• Roy K. On some aspects of validation of predictive quantitative structure–activity relationship models. Expert Opin Drug Discov. 2007;2(12):1567–1577.
   PubMed Web of Science ®Google Scholar
• Dhiman K, Agarwal SM. NPred: QSAR classification model for identifying plant based naturally occurring anti-cancerous inhibitors. RSC Adv. 2016;6(55):49395–49400.
   Web of Science ®Google Scholar
• Eriksson L, Jaworska J, Worth AP, et al. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environ Health Perspect. 2003;111(10):1361–1375.
   PubMed Web of Science ®Google Scholar